<?xml version='1.0' encoding='utf-8'?>
<document id="30975793"><sentence text="Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: &quot;SLC-Phenotyping&quot; Using Primary Human Hepatocytes." /><sentence text="Hepatic uptake transporters [solute carriers (SLCs)], including organic anion transporting polypeptide (OATP) 1B1, OATP1B3, OATP2B1, sodium-dependent taurocholate cotransporting polypeptide (NTCP), and organic anion (OAT2) and organic cation (OCT1) transporters, play a key role in determining the systemic and liver exposure of chemically diverse drugs"><entity charOffset="133-139" id="DDI-PubMed.30975793.s2.e0" text="sodium" /><entity charOffset="150-162" id="DDI-PubMed.30975793.s2.e1" text="taurocholate" /><pair ddi="false" e1="DDI-PubMed.30975793.s2.e0" e2="DDI-PubMed.30975793.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30975793.s2.e0" e2="DDI-PubMed.30975793.s2.e1" /></sentence><sentence text=" Here, we established a phenotyping approach to quantify the contribution of the six SLCs, and passive diffusion, to the overall uptake using plated human hepatocytes (PHHs)" /><sentence text=" First, selective inhibitor conditions were identified by screening about 20 inhibitors across the six SLCs using single-transfected human embryonic kidney 293 cells" /><sentence text=" Data implied rifamycin SV (20 µM) inhibits three OATPs, while rifampicin (5 µM) inhibits OATP1B1/1B3 only"><entity charOffset="14-26" id="DDI-PubMed.30975793.s5.e0" text="rifamycin SV" /><entity charOffset="63-73" id="DDI-PubMed.30975793.s5.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.30975793.s5.e0" e2="DDI-PubMed.30975793.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30975793.s5.e0" e2="DDI-PubMed.30975793.s5.e1" /></sentence><sentence text=" Further, hepatitis B virus myristoylated-preS1 peptide (0" /><sentence text="1 µM), quinidine (100 µM), and ketoprofen (100-300 µM) are relatively selective against NTCP, OCT1, and OAT2, respectively"><entity charOffset="7-16" id="DDI-PubMed.30975793.s7.e0" text="quinidine" /><entity charOffset="31-41" id="DDI-PubMed.30975793.s7.e1" text="ketoprofen" /><pair ddi="false" e1="DDI-PubMed.30975793.s7.e0" e2="DDI-PubMed.30975793.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30975793.s7.e0" e2="DDI-PubMed.30975793.s7.e1" /></sentence><sentence text=" Second, using these inhibitory conditions, the fraction transported (ft ) by the individual SLCs was characterized for 20 substrates with PHH" /><sentence text=" Generally, extended clearance classification system class 1A/3A (e" /><sentence text="g" /><sentence text=", warfarin) and 1B/3B compounds (e" /><sentence text="g" /><sentence text=", statins) showed predominant OAT2 and OATP1B1/1B3 contribution, respectively" /><sentence text=" OCT1-mediated uptake was prominent for class 2/4 compounds (e" /><sentence text="g" /><sentence text=", metformin)"><entity charOffset="2-11" id="DDI-PubMed.30975793.s16.e0" text="metformin" /></sentence><sentence text=" Third, in vitro ft values were corrected using quantitative proteomics data to obtain &quot;scaled ft &quot; Fourth, in vitro-in vivo extrapolation of the scaled OATP1B1/1B3 ft was assessed, leveraging statin clinical drug-drug interaction data with rifampicin as the perpetrator"><entity charOffset="241-251" id="DDI-PubMed.30975793.s17.e0" text="rifampicin" /></sentence><sentence text=" Finally, we outlined a novel stepwise strategy to implement phenotypic characterization of SLC-mediated hepatic uptake for new molecular entities and drugs in a drug discovery and development setting" /><sentence text="" /></document>